

# Contents

|                                                                                                |    |
|------------------------------------------------------------------------------------------------|----|
| <b>Introduction</b> . . . . .                                                                  | 1  |
| <b>Coronary Atherosclerosis: General Considerations</b> . . . . .                              | 7  |
| Epidemiology of Coronary Atherosclerosis . . . . .                                             | 7  |
| Clinical Manifestations of Coronary Atherosclerosis . . . . .                                  | 8  |
| General Therapeutic Measures in Angina Pectoris . . . . .                                      | 8  |
| Physical Training in Angina Pectoris . . . . .                                                 | 8  |
| Treatment of Determining Factors of Atherosclerosis                                            |    |
| — of Formed Anatomical Lesions; Surgery . . . . .                                              | 10 |
| — of Predisposing Factors . . . . .                                                            | 14 |
| a) Hypercholesterolaemia and Hypertriglyceridaemia . . . . .                                   | 14 |
| b) High Blood Pressure . . . . .                                                               | 16 |
| c) Metabolic Diseases . . . . .                                                                | 16 |
| d) Tobacco . . . . .                                                                           | 16 |
| — of the Anginal Syndrome . . . . .                                                            | 17 |
| <b>I. Pathophysiology of Angina Pectoris</b> . . . . .                                         | 19 |
| 1. Pathophysiology of the Anginal Attack . . . . .                                             | 23 |
| Imbalance Between Myocardial Oxygen Consumption and Coronary Blood Flow . . . . .              | 23 |
| Lactate Production . . . . .                                                                   | 25 |
| Myocardial Electrolyte Balance . . . . .                                                       | 26 |
| Robinson's Index . . . . .                                                                     | 29 |
| 2. Cardiac Dynamics during the Anginal Attack . . . . .                                        | 30 |
| 3. Part Played by Hypersympathicotony in the Anginal Attack . . . . .                          | 35 |
| 4. Trends in Pharmacological Research for the Development of Antianginal Medications . . . . . | 39 |
| 4.1. Coronary Vaso-Dilation . . . . .                                                          | 39 |
| 4.2. Reduction in Cardiac Work . . . . .                                                       | 40 |
| 4.3. Inhibition of Monoamineoxydase . . . . .                                                  | 41 |
| 4.4. Blockade of Hypersympathicotony . . . . .                                                 | 42 |
| 4.5. Blockade of the Adrenergic $\beta$ -Receptors . . . . .                                   | 42 |
| 4.6. Overall Inhibition of Hypersympathicotony . . . . .                                       | 43 |
| 4.7. Dilatation of the Coronary Conductance Vessels . . . . .                                  | 44 |
| 4.8. Improvement of Functional Coronary Microcirculation . . . . .                             | 45 |
| 4.9. Development of a Collateral Coronary Circulation . . . . .                                | 45 |
| 4.10. Potentiation of the Endogenous Mediators of the Coronary Autoregulation . . . . .        | 47 |
| 4.11. Prophylaxis of Myocardial Necrosis . . . . .                                             | 48 |
| 4.12. Inhibition of Platelet Aggregation or Adhesiveness . . . . .                             | 49 |
| <b>II. Haemodynamic Basis for Coronary Pharmacology</b> . . . . .                              | 52 |
| General Considerations . . . . .                                                               | 52 |
| Blood Pressure . . . . .                                                                       | 55 |
| Myocardial Oxygen Consumption . . . . .                                                        | 55 |
| Cardiac Work . . . . .                                                                         | 56 |
| Cardiac Output . . . . .                                                                       | 56 |
| Heart Rate . . . . .                                                                           | 56 |
| Regulation of Coronary Circulation . . . . .                                                   | 58 |
| Hypoxaemia . . . . .                                                                           | 59 |
| Vasomotor Metabolites . . . . .                                                                | 59 |
| CO <sub>2</sub> . . . . .                                                                      | 59 |
| Lactic Acid . . . . .                                                                          | 59 |

|                                                                                                          |           |
|----------------------------------------------------------------------------------------------------------|-----------|
| pH . . . . .                                                                                             | 59        |
| Histamine . . . . .                                                                                      | 60        |
| Potassium . . . . .                                                                                      | 60        |
| Adenosine . . . . .                                                                                      | 60        |
| "Sympathine" . . . . .                                                                                   | 62        |
| Bradykinine . . . . .                                                                                    | 63        |
| Hyperemine . . . . .                                                                                     | 64        |
| <b>III. Pharmacological Methodology for Testing Antianginal Drugs . . . . .</b>                          | <b>65</b> |
| Coronary Blood Flow . . . . .                                                                            | 65        |
| Isolated Heart . . . . .                                                                                 | 65        |
| Heart <i>in situ</i> . . . . .                                                                           | 68        |
| 1. <i>Measurement of Coronary Outflow</i> . . . . .                                                      | 68        |
| 1.1. Morawitz Technique . . . . .                                                                        | 70        |
| 1.2. Heart-Lung Preparation . . . . .                                                                    | 70        |
| 1.3. Rodbard Technique . . . . .                                                                         | 70        |
| 1.4. Busch Technique . . . . .                                                                           | 71        |
| 1.5. Catheterization of the Coronary Sinus without Thoracotomy . . . . .                                 | 71        |
| 2. <i>Measurement of Coronary Inflow</i> . . . . .                                                       | 72        |
| 2.1. Techniques with Extra-Arterial Cannulation . . . . .                                                | 72        |
| 2.1.1. Melville Technique . . . . .                                                                      | 72        |
| 2.1.2. Schofield Technique . . . . .                                                                     | 72        |
| 2.2. Techniques with Intra-Arterial Cannulation . . . . .                                                | 73        |
| 2.2.1. Gregg Technique . . . . .                                                                         | 73        |
| 2.2.2. Pieper Technique . . . . .                                                                        | 74        |
| 2.2.3. Berne Technique . . . . .                                                                         | 74        |
| 2.3. Techniques without Arterial Cannulation . . . . .                                                   | 75        |
| 2.3.1. Direct Methods . . . . .                                                                          | 75        |
| 2.3.1.1. The Thermostromuhr . . . . .                                                                    | 76        |
| 2.3.1.2. The Calorimetric Method . . . . .                                                               | 76        |
| 2.3.1.3. Method Using the Electromagnetic Flow Transducer . . . . .                                      | 77        |
| 2.3.1.4. Method Using the Ultrasonic Flowmeter . . . . .                                                 | 78        |
| 2.3.2. Indirect Methods . . . . .                                                                        | 79        |
| 2.3.2.1. The Nitrous Oxide Technique . . . . .                                                           | 79        |
| 2.3.2.2. Methods Based on the Employment of Radioactive Substances . . . . .                             | 81        |
| 2.3.2.2.1. Non-diffusible Substances . . . . .                                                           | 81        |
| 2.3.2.2.2. Diffusible Substances . . . . .                                                               | 81        |
| 2.3.2.2.3. Diffusible Inert Gases . . . . .                                                              | 83        |
| 3. <i>Nutritional Myocardial Micro-Circulation</i> . . . . .                                             | 85        |
| 4. <i>Collateral Coronary Circulation</i> . . . . .                                                      | 85        |
| 4.1. Acute Experiment . . . . .                                                                          | 85        |
| 4.1.1. Linder Technique . . . . .                                                                        | 85        |
| 4.1.2. Rees Technique . . . . .                                                                          | 85        |
| 4.1.3. McGregor Technique . . . . .                                                                      | 85        |
| 4.2. Chronic Experiment . . . . .                                                                        | 86        |
| 4.2.1. Meesmann Technique . . . . .                                                                      | 86        |
| 4.2.2. Schmidt Technique . . . . .                                                                       | 86        |
| 4.2.3. Schaper Technique . . . . .                                                                       | 86        |
| 5. <i>Experimental Chronic Coronary Insufficiency</i> . . . . .                                          | 87        |
| Measuring Cardiac Output . . . . .                                                                       | 90        |
| Measuring Cardiac Work . . . . .                                                                         | 92        |
| Measuring Myocardial Oxygen Consumption . . . . .                                                        | 92        |
| <b>IV. Clinical Methods for Assessment of the Therapeutic Value of Antianginal Medications . . . . .</b> | <b>95</b> |
| Diagnosis of Angina Pectoris . . . . .                                                                   | 95        |
| Clinical Assessment of Antianginal Drugs . . . . .                                                       | 101       |
| 1. Objective Methods . . . . .                                                                           | 102       |
| 1.1. Russek Method . . . . .                                                                             | 102       |
| 1.2. Levy Method . . . . .                                                                               | 106       |

|                                                                                        |            |
|----------------------------------------------------------------------------------------|------------|
| 1.3. Riseman Method . . . . .                                                          | 106        |
| 1.4. Solvay Method . . . . .                                                           | 108        |
| 1.5. Rookmaker Method . . . . .                                                        | 109        |
| 1.6. Frick Method . . . . .                                                            | 109        |
| 2. Subjective Methods . . . . .                                                        | 109        |
| Greiner Method . . . . .                                                               | 111        |
| 3. Conclusions on Methods of Clinical Assessment . . . . .                             | 116        |
| <b>V. Pharmacological and Clinical Features of Antianginal Drugs . . . . .</b>         | <b>118</b> |
| Nitrites . . . . .                                                                     | 118        |
| 1. Nitroglycerin . . . . .                                                             | 120        |
| — Effect on Coronary Flow in Dogs . . . . .                                            | 123        |
| — Effect on Coronary Flow in Humans . . . . .                                          | 125        |
| — Haemodynamic Effects in Humans . . . . .                                             | 126        |
| — Haemodynamic Effects in the Case of the Angina Patient Suffering an Attack . . . . . | 128        |
| — Mechanisms of the Antianginal Effect . . . . .                                       | 129        |
| — Therapeutic Effect of Nitroglycerin . . . . .                                        | 135        |
| — Special Galenic Preparations . . . . .                                               | 137        |
| 2. Triethanolamine Trinitrate . . . . .                                                | 138        |
| 3. Erythryl Tetranitrate . . . . .                                                     | 140        |
| 4. Pentaerythritol Tetranitrate . . . . .                                              | 140        |
| 5. Mannitol Hexanitrate . . . . .                                                      | 143        |
| 6. Amyl Nitrite . . . . .                                                              | 143        |
| 7. Octyl Nitrite . . . . .                                                             | 144        |
| 8. Sodium Nitrite . . . . .                                                            | 145        |
| 9. Isosorbide Dinitrate . . . . .                                                      | 146        |
| 10. Nitatil . . . . .                                                                  | 148        |
| 11. Etrynit . . . . .                                                                  | 149        |
| 12. Propanediol Dinitrates . . . . .                                                   | 149        |
| Papaverine . . . . .                                                                   | 150        |
| Xanthines . . . . .                                                                    | 152        |
| 1. Aminophylline . . . . .                                                             | 153        |
| 2. Choline Theophyllinate . . . . .                                                    | 155        |
| 3. Various Theophylline Derivatives . . . . .                                          | 155        |
| Khellin . . . . .                                                                      | 157        |
| Carduben . . . . .                                                                     | 159        |
| Diacromone . . . . .                                                                   | 159        |
| Phenyl-chromone . . . . .                                                              | 160        |
| Recordil . . . . .                                                                     | 160        |
| Monoamineoxydase Inhibitors (Maoi) . . . . .                                           | 160        |
| Irrigor . . . . .                                                                      | 164        |
| Segontin . . . . .                                                                     | 165        |
| Amplivix . . . . .                                                                     | 168        |
| Isoptin . . . . .                                                                      | 172        |
| Persantine . . . . .                                                                   | 181        |
| Intensaine . . . . .                                                                   | 188        |
| Ustimon . . . . .                                                                      | 192        |
| Ildamen . . . . .                                                                      | 196        |
| Clinium . . . . .                                                                      | 199        |
| <b><math>\beta</math>-Adrenergic Blocking Drugs . . . . .</b>                          | <b>205</b> |
| 1. Inderal . . . . .                                                                   | 206        |
| — Primary Cardiac Effect . . . . .                                                     | 207        |
| — Effect on Coronary Flow . . . . .                                                    | 208        |
| — Effect on Cardiac Output . . . . .                                                   | 210        |
| — Antianginal Effect . . . . .                                                         | 211        |
| — Mechanisms of the Antianginal Effect . . . . .                                       | 214        |
| — Effect on the Cardiac Function . . . . .                                             | 215        |
| — Recommendations for the Treatment of Angina Pectoris . . . . .                       | 217        |

|                                                                             |     |
|-----------------------------------------------------------------------------|-----|
| — Ineffectiveness of Inderal in Acute Myocardial Infarction . . . . .       | 217 |
| — The Use of Inderal in Cardiac Arrhythmia . . . . .                        | 218 |
| 2. Trasacor . . . . .                                                       | 222 |
| Clinical Application . . . . .                                              | 227 |
| 3. Aptin . . . . .                                                          | 229 |
| 4. Eraldin . . . . .                                                        | 235 |
| 5. ICI 45763 or Kō 592 (doberol) . . . . .                                  | 245 |
| 6. Viskin (LB 46) . . . . .                                                 | 246 |
| 7. Ro 3-3528 . . . . .                                                      | 248 |
| 8. INPEA . . . . .                                                          | 248 |
| 9. Sotalol (M.J. 1999) . . . . .                                            | 249 |
| 10. Recetan . . . . .                                                       | 252 |
| 11. PhQA 33 . . . . .                                                       | 253 |
| 12. AH 3474 . . . . .                                                       | 253 |
| 13. D 477 A . . . . .                                                       | 254 |
| 14. USVC 6524 . . . . .                                                     | 254 |
| 15. S-D/1601 . . . . .                                                      | 254 |
| 16. Bunolol . . . . .                                                       | 255 |
| Cordarone . . . . .                                                         | 255 |
| 1. Pharmacological Properties . . . . .                                     | 256 |
| 1.1. Intrinsic Effects . . . . .                                            | 256 |
| 1.2. Antiadrenergic Effects . . . . .                                       | 262 |
| 1.2.1. $\alpha$ -antiadrenergic Effects . . . . .                           | 262 |
| 1.2.2. $\beta$ -antiadrenergic Effects . . . . .                            | 263 |
| 1.3. Action Mechanisms and Therapeutic Deductions . . . . .                 | 266 |
| 1.3.1. Intrinsic Effects . . . . .                                          | 266 |
| 1.3.2. Antiadrenergic Effects . . . . .                                     | 271 |
| 1.4. Anti-Arrhythmic Properties . . . . .                                   | 276 |
| 2. Therapeutic Properties . . . . .                                         | 276 |
| 2.1. Antianginal Effects in Open Tests . . . . .                            | 276 |
| 2.2. Antianginal Effects in Double-Blind Tests . . . . .                    | 279 |
| 2.3. Effects on the Symptomatology of the Cardiac Overload Tests . . . . .  | 280 |
| 2.3.1. Hypoxia Test . . . . .                                               | 280 |
| 2.3.2. Ergometric Bicycle Test . . . . .                                    | 280 |
| 2.3.3. Master Type Effort Test . . . . .                                    | 284 |
| 2.4. Effects on Pathological Electrocardiogram in Coronary Angina . . . . . | 285 |
| 2.5. Anti-Arrhythmic Effects . . . . .                                      | 285 |
| 2.6. Clinical Tolerance and Side Effects . . . . .                          | 286 |
| Miscellaneous . . . . .                                                     | 288 |
| <i>Section no. 1</i> . . . . .                                              | 288 |
| Adenylocrat . . . . .                                                       | 288 |
| Aminocetone . . . . .                                                       | 288 |
| Anginin . . . . .                                                           | 289 |
| Baralgin . . . . .                                                          | 289 |
| Baxacor . . . . .                                                           | 289 |
| Eucilat . . . . .                                                           | 291 |
| Griseofulvine . . . . .                                                     | 291 |
| Mederel . . . . .                                                           | 292 |
| Opticardon . . . . .                                                        | 293 |
| Pexid . . . . .                                                             | 293 |
| Piridoxilate . . . . .                                                      | 294 |
| Polarising Solutions . . . . .                                              | 295 |
| Sandolanid . . . . .                                                        | 296 |
| Surheme . . . . .                                                           | 297 |
| Terodiline . . . . .                                                        | 297 |
| Tromcardin . . . . .                                                        | 298 |
| Vastarel . . . . .                                                          | 298 |
| Vialibran . . . . .                                                         | 298 |

|                                                   |         |
|---------------------------------------------------|---------|
| <i>Section no. 2</i> . . . . .                    | 299     |
| Morphine . . . . .                                | 299     |
| Barbiturates . . . . .                            | 299     |
| Ethyl Alcohol . . . . .                           | 300     |
| Valium . . . . .                                  | 301     |
| Phenothiazines . . . . .                          | 302     |
| Chlorpromazine . . . . .                          | 302     |
| Mepazine . . . . .                                | 303     |
| Chloracizine . . . . .                            | 303     |
| Diphenylhydantoin . . . . .                       | 303     |
| Cinchona Alkaloids . . . . .                      | 303     |
| Daucarine . . . . .                               | 304     |
| Vitamin E . . . . .                               | 305     |
| Hexoestrol . . . . .                              | 305     |
| Adenosine and Related Substances . . . . .        | 305     |
| Thyroxine . . . . .                               | 306     |
| <br><i>Section no. 3</i> . . . . .                | <br>307 |
| Phenoxy-Isopropyl-Norsuprifen . . . . .           | 307     |
| Phenyl-Isobutyl-Norsuprifen . . . . .             | 307     |
| Cyclospasmol . . . . .                            | 308     |
| Vasculat . . . . .                                | 308     |
| Reserpine . . . . .                               | 308     |
| Padutin . . . . .                                 | 309     |
| Recosen . . . . .                                 | 309     |
| Cortunon . . . . .                                | 310     |
| Heparin . . . . .                                 | 310     |
| Dicoumarol . . . . .                              | 311     |
| Ilidar . . . . .                                  | 312     |
| Priscol . . . . .                                 | 312     |
| Hydergine . . . . .                               | 312     |
| Ronicol . . . . .                                 | 313     |
| Poly-Methoxyphenol Derivatives . . . . .          | 313     |
| Triparanol . . . . .                              | 314     |
| Varia . . . . .                                   | 314     |
| <i>Carotid Sinus Nerve Stimulation</i> . . . . .  | 315     |
| Prospects of future research . . . . .            | 316     |
| <br><b>Table of Side Effects in Man</b> . . . . . | <br>320 |
| <br><b>References</b> . . . . .                   | <br>323 |
| <br><b>Author Index</b> . . . . .                 | <br>372 |
| <br><b>Subject Index</b> . . . . .                | <br>431 |